SpringWorks Therapeutics (SWTX) Revenue & Revenue Breakdown
SpringWorks Therapeutics Revenue Highlights
Latest Revenue (Y)
$5.45M
Latest Revenue (Q)
$59.73M
SpringWorks Therapeutics Revenue by Period
SpringWorks Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $5.45M | -11.39% |
2022-12-31 | $6.15M | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $35.00M | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
SpringWorks Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $59.73M | 184.36% |
2024-03-31 | $21.01M | 285.64% |
2023-12-31 | $5.45M | -2.49% |
2023-09-30 | $5.59M | -4.15% |
2023-06-30 | $5.83M | 4.88% |
2023-03-31 | $5.56M | -4.17% |
2022-12-31 | $5.80M | 592.00% |
2022-09-30 | $838.00K | 140.80% |
2022-06-30 | $348.00K | 6860.00% |
2022-03-31 | $5.00K | 100.00% |
2021-12-31 | - | -100.00% |
2021-09-30 | $121.00K | -28.82% |
2021-06-30 | $170.00K | -26.09% |
2021-03-31 | $230.00K | -99.34% |
2020-12-31 | $35.00M | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
SpringWorks Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
KYMR | Kymera Therapeutics | $78.59M | $3.74M |
ARVN | Arvinas | $78.50M | $102.40M |
RLAY | Relay Therapeutics | $25.55M | - |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
RNA | Avidity Biosciences | $9.56M | $2.04M |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
SWTX | SpringWorks Therapeutics | $5.45M | $59.73M |
PLRX | Pliant Therapeutics | $1.58M | - |
BCEL | Atreca | $770.00K | $80.00K |
BDTX | Black Diamond Therapeutics | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
CERE | Cerevel Therapeutics | - | - |
PASG | Passage Bio | - | - |
TERN | Terns Pharmaceuticals | - | - |
SANA | Sana Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |